445 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Oct 16
Bristol-Myers Squibb Reports Third Quarter Financial Results
12:00am
-label, single-arm study assessing the safety and efficacy of Opdivo in patients with locally advanced unresectable or mUC that has progressed after … . There were no new safety signals identified for Opdivo in the pooled safety analysis from both studies.
CheckMate -016: Updated results from
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Mar 20
Other Events
9:15am
of safety stock and are at an appropriate level based on anticipated needs.
At this time, we are not seeing disruptions to our ability to supply … in place and are successfully mitigating these challenges.
Workforce
We have implemented a number of measures to protect the health and safety of our
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
24 Aug 12
Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
Company will share BMS-986094 data with other companies developing similar hepatitis C drugs to inform patient safety measures
(Princeton, NJ, August 23 … of patient safety, based on a rapid, thorough and ongoing assessment of patients in a Phase II study that the Company voluntarily suspended on August
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
3 Aug 12
Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause … of the safety issue and any potential relationship to study drug are unknown at this time.
With patient safety as the priority, the Company is undertaking
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
23 Jul 15
Bristol-Myers Squibb Reports Second Quarter Financial Results
12:00am
. The safety profile of Opdivo in CheckMate -057 was favorable versus docetaxel with grade 3-5 treatment-related adverse events reported in 10% of patients … % for docetaxel, with a median overall survival of 9.2 months versus 6 months, respectively. Opdivo reduced the risk of death by 41%. The safety profile of Opdivo
425
6bblz4eqc55 7n
25 Mar 19
Business combination disclosure
5:25pm
8-K
EX-99.1
f2hpw6b33ji6lod43
27 Oct 15
Bristol-Myers Squibb Reports Third Quarter Financial Results
12:00am
8-K
EX-10.4
y3y14o
17 Aug 09
Other Events
12:00am
425
hh0a8
19 Mar 19
Business combination disclosure
7:04am
8-K
t8l ik6nrbktyb3cdk
3 Aug 12
Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C
12:00am
8-K
EX-10.6
qktdr6
17 Aug 09
Other Events
12:00am
8-K
EX-99.1
4ihi io93
16 Nov 21
Regulation FD Disclosure
9:20am
8-K
EX-99.3
bllrr8vnzqbssz
24 Jan 19
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
8:54am
425
xk1jai2s16tabyc4qz0
6 Mar 19
Business combination disclosure
7:03am
SC TO-T/A
EX-99
mqbmhmr rkur
19 Jan 12
Third party tender offer statement (amended)
12:00am
DFAN14A
EX-99.1
xskpzpl1
22 Dec 23
Additional proxy materials by non-management
4:21pm
8-K
EX-99.1
2glt14sr
25 Jul 13
Bristol-Myers Squibb Reports Second Quarter 2013 Financial Results
12:00am
8-K
EX-99.1
noun f1f0ryhr
25 Oct 18
Bristol-Myers Squibb Reports Third Quarter Financial Results
8:02am
8-K
EX-99.1
sd0zxas
22 Dec 23
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
4:15pm